Breakthrough Rhizopus infection on posaconazole prophylaxis following allogeneic stem cell transplantation

Schlemmer, F.; Lagrange-Xélot, Marie; Lacroix, Claire; Tour, Roberto de la; Socié, Gèrard; Molina, Jean‐Michel

doi:10.1038/bmt.2008.199

Cited by 41 publications

(29 citation statements)

References 11 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…22 Nevertheless, there are also emerging reports of breakthrough infections by agents of mucormycosis in patients receiving prophylactic posaconazole. [74][75][76] This means that even if a patient is on posaconazole prophylaxis, mucormycosis should be included in the differential diagnosis if signs of an invasive fungal infection are found.…”

Section: Posaconazolementioning

confidence: 99%

Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3)

et al. 2012

View full text Add to dashboard Cite

Section: Posaconazolementioning

confidence: 99%

Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3)

et al. 2012

View full text Add to dashboard Cite

“…Indeed, outbreaks of mucormycosis cases in patients who received VOR prophylaxis are frequently described (6,(11)(12)(13)(14). In contrast, POS has activity against Mucorales in vitro, but breakthrough mucormycosis infections (especially with Rhizopus species) among patients who received POS prophylaxis have also been reported (15,16).…”

mentioning

confidence: 99%

Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis

Gebremariam

Alkhazraji

Baldin

et al. 2017

Antimicrob Agents Chemother

View full text Add to dashboard Cite

We assessed prophylactic or continuous therapy of isavuconazole, posaconazole, or voriconazole in treating pulmonary murine mucormycosis. In the prophylaxis studies, only isavuconazole treatment resulted in significantly improved survival and lowered tissue fungal burden of immunosuppressed mice infected with Rhizopus delemar. In the continuous treatment studies, isavuconazole and posaconazole, but not voriconazole, equally prolonged survival time and lowered tissue fungal burden compared to placebo-treated mice. These results support the use of isavuconazole and posaconazole in prophylaxis treatment.

show abstract

“…IMIs other than IA (reported in only 6 of 605 patients receiving posaconazole prophylaxis in the RCTs) have now been reported in several patients during treatment with the drug [38,39]. Also, reports were published of IA and invasive candidiasis [40].…”

Section: Breakthrough Invasive Fungal Infectionmentioning

confidence: 96%

Risk-based antifungal prophylaxis in hematologic malignancy and stem cell transplantation

Wolf

Slavin

2009

Curr Infect Dis Rep

View full text Add to dashboard Cite

Invasive fungal infection (IFI) is an important cause of morbidity and mortality in patients with hematologic malignancy, prolonged neutropenia, or after hematopoietic stem cell transplant. Antifungal prophylaxis prevents IFI in high-risk hematology patients. This article discusses recent developments in antifungal prophylaxis, focusing on those expected to affect patient management. Significant advances have occurred in understanding risk stratification and assessment of individual patient risk for drug-drug interactions, toxicity, or variations in pharmacokinetics; choice of antifungal prophylaxis strategy, drug, dose, route, and regimen; therapeutic drug monitoring; cost effectiveness of prophylaxis; and the significance of breakthrough IFI. Research over the coming decade is likely to fundamentally alter antifungal prophylaxis by allowing clinicians to make individualized decisions for their patients informed by rapid, detailed, and personalized risk-benefit analyses.

show abstract

Breakthrough Rhizopus infection on posaconazole prophylaxis following allogeneic stem cell transplantation

Cited by 41 publications

References 11 publications

Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3)

Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3)

Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis

Risk-based antifungal prophylaxis in hematologic malignancy and stem cell transplantation

Contact Info

Product

Resources

About